Apremilast

Overview

Apremilast (CC-10004) is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase ( PDE-4 ) with an IC 50 of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC 50 of 104 nM.

Application

Products | Products > Disease Areas > Respiratory Disease | Products > Disease Areas > Digestive System Disease | Products > Disease Areas > Urogenital Disease | Products > Disease Areas > Musculoskeletal and Skin Disease | Products > Disease Areas > Neurodegenerative Disease | Products > Disease Areas > Pulmonary Disease | Products > Disease Areas > Autoimmune Disease | Products > Disease Areas > Arthritis | Products > Disease Areas > Colorectal Cancer | Products > Disease Areas > Digestive System Cancer | Products > Disease Areas > Prostate Cancer | Products > Disease Areas > Urogenital Cancer | Products > Disease Areas > Depression | Products > Disease Areas > Pain | Products > Disease Areas > Digestive System Inflammation | Products > Disease Areas > Alzheimer's Disease | Products > Disease Areas > Lung Fibrosis | Products > Disease Areas > Rheumatoid Arthritis | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Inflammation or Immune System Disease | Products > Signaling Pathways > Metabolic Enzyme/Protease | Products > Signaling Pathways > Apoptosis | Products > Research Areas > Inflammation/Immunology | Products > Signaling Pathways > Phosphodiesterase (PDE) | Products > Signaling Pathways > Apoptosis | Products > Signaling Pathways > TNF Receptor

Product Information

• Catalog No.: HY-12085
• CAS No.: 608141-41-9
• Molecular Formula: C22H24N2O7S
• Molecular Weight: 460.50
• Purity: 99.79%
• Storage: Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 1 year , -20°C, 6 months
• Solubility: ≥ 2.5 mg/mL (5.43 mM); Clear solution
• Availability: In-stock

Source

Original product source